Kamada (KMDA) Gross Margin (2012 - 2026)
Kamada's (KMDA) quarterly Gross Margin came in at 40.91% in Q2 2026, down 139.0% on a YoY basis from 104.89% in Q2 2025, and down 3.19% quarter-over-quarter from 42.25% in Q1 2026.
Analysis
Kamada (KMDA) Gross Margin (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Gross Margin for 15 consecutive years, with 40.91% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Gross Margin fell 139.0% year-over-year to 40.91%; the trailing twelve-month figure through Jun 2026 stood at 40.82% (down 280.0% YoY), and the FY2025 full-year result was 42.34%, down 113.0% from the prior year.
- Gross Margin retreated to 40.91% in Q2 2026 per KMDA's latest filing, from 42.25% in the prior quarter.
- Across five years, Gross Margin topped out at 47.14% in Q1 2025 and bottomed at 30.69% in Q2 2022.
- Historically, Gross Margin has averaged 40.38% across 5 years, with a median of 40.57% in 2022.
- The widest YoY moves for Gross Margin: up 1507 bps in 2022, down 674 bps in 2022.
- Over 5 years, Gross Margin stood at 33.65% in 2022, then advanced by 18 bps to 39.56% in 2023, then rose by 10 bps to 43.66% in 2024, then slipped by 13 bps to 37.98% in 2025, then gained by 8 bps to 40.91% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 40.91%, 42.25%, and 37.98% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.30 Bn | 197.31 Bn | 7.24 Bn | 72.04% |
| 2 | Gilead Sciences | 180.97 Bn | 177.79 Bn | 6.22 Bn | 79.76% |
| 3 | Vertex Pharmaceuticals | 132.27 Bn | 124.42 Bn | 2.84 Bn | 85.33% |
| 4 | Regeneron Pharmaceuticals | 82.93 Bn | 74.93 Bn | 3.93 Bn | 91.59% |
| 5 | Argenx Se | 61.53 Bn | 56.35 Bn | 1.37 Bn | 90.43% |
| 6 | Moderna | 54.27 Bn | 49.13 Bn | 52.00 Mn | 35.86% |
| 7 | Alnylam Pharmaceuticals | 34.46 Bn | 31.15 Bn | 992.69 Mn | 76.90% |
| 8 | Biogen | 31.16 Bn | 29.88 Bn | 1.96 Bn | 71.60% |
| 9 | Roivant Sciences | 30.08 Bn | 30.08 Bn | 1.16 Mn | 80.31% |
| 10 | Kamada | 473.85 Mn | 403.72 Mn | 22.47 Mn | 40.91% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 40.91% |
| Mar 31, 2026 | 42.25% |
| Dec 31, 2025 | 37.98% |
| Sep 30, 2025 | 42.04% |
| Jun 30, 2025 | 42.30% |
| Mar 31, 2025 | 47.14% |
| Dec 31, 2024 | 43.66% |
| Sep 30, 2024 | 41.29% |
| Jun 30, 2024 | 44.62% |
| Mar 31, 2024 | 44.39% |
| Dec 31, 2023 | 39.56% |
| Sep 30, 2023 | 39.02% |
| Jun 30, 2023 | 38.55% |
| Mar 31, 2023 | 38.55% |
| Dec 31, 2022 | 33.65% |
| Sep 30, 2022 | 39.95% |
| Jun 30, 2022 | 30.69% |
| Mar 31, 2022 | 40.23% |
| Dec 31, 2021 | 20.96% |
| Sep 30, 2021 | 24.88% |